Skip to content
IV/SC Injection Allopathic

Bortezomib Ever Pharma 3.5 mg/vial iv/sc injection

Generic: Bortezomib

Company: ZAS Corporation. Prices are as listed on BestinMeds; your pharmacy price may differ.

Strength3.5 mg/vial
PackNot listed yet

Reviewed by: not listed yet. Source: not listed yet.

Last updated April 15, 2025.

Compare

Same generic, same strength

Sorted by price per iv/sc injection. Ask your pharmacist before you switch brands.

Bortezomib 3.5 mg/vial iv/sc injections

Prices as listed on BestinMeds.

No price is listed for this strength yet.

Advertisement

Google Ads 970 x 250
Google Ads 300 x 250
Medicine guide

About this medicine

What this medicine is for, how to take it, and what to watch for.

Read the full Bortezomib guide

Indications

Multiple myeloma Bortezomib is a proteasome inhibitor indicated for: Treatment of patients with multiple myeloma Treatment of patients with mantle cell lymphoma who have received at least 1 prior therapy

Dosage and administration

The recommended dose of Bortezomib is 1.3 mg/m2 administered as a 3 to 5 second bolus intravenous injection. Dose adjustment may be used to manage adverse events that occur during treatment

Side effects

Most commonly reported adverse reactions (incidence ≥30%) in clinical studies include asthenic conditions, diarrhea, nausea, constipation, peripheral neuropathy, vomiting, pyrexia, thrombocytopenia, psychiatric disorders, anorexia and decreased appetite, neutropenia, neuralgia, leukopenia and anemia. Other adverse reactions, including serious adverse reactions, have been reported

Precautions and warnings

Women should avoid becoming pregnant while being treated with Bortezomib. Pregnant women should be apprised of the potential harm to the fetus Peripheral neuropathy, including severe cases, may occur - manage with dose modification or discontinuation. Patients with preexisting severe neuropathy should be treated with Bortezomib only after careful risk-benefit assessment. Hypotension can occur. Caution should be used when treating patients receiving antihypertensives, those with a history of syncope, and those who are dehydrated. Patients with risk factors for, or existing heart disease, should be closely monitored. Acute diffuse infiltrative pulmonary disease has been reported. Nausea, diarrhea, constipation, and vomiting have occurred and may require use of antiemetic and antidiarrheal medications or fluid replacement. Thrombocytopenia or neutropenia can occur; complete blood counts should be regularly monitored throughout treatment. Tumor Lysis Syndrome, Reversible Posterior Leukoencephalopathy Syndrome, and acute hepatic failure have been reported.

Pregnancy and lactation

Pregnancy Category D. Women of childbearing potential should avoid becoming pregnant while being treated with Bortezomib. Bortezomib administered to rabbits during organogenesis at a dose approximately 0.5 times the clinical dose of 1.3 mg/m2 based on body surface area caused post implantation loss and a decreased number of live fetuses.

Clinical details

BestinMeds shares medicine information to help you compare. It does not replace advice from your doctor or pharmacist.

Advertisement

Google Ads 970 x 250
Google Ads 300 x 250

Advertisement

Google Ads 970 x 250
Google Ads 300 x 250